Novo Nordisk A/S (NVO) - Stock Price & Dividends

Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Novo Nordisk A/S, along with its subsidiaries, conducts research and development, as well as the manufacturing and distribution of pharmaceutical products globally. Their reach extends across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. The company operates in two distinct segments, namely Diabetes and Obesity Care, and Rare Disease.

The Diabetes and Obesity Care segment focuses on providing products catering to diabetes, obesity, cardiovascular, and other emerging therapy areas. On the other hand, the Rare Disease segment specializes in offering products related to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk A/S also offers a range of medical devices, including insulin pens, growth hormone pens, and injection needles.

Moreover, the company is known for its innovative approach to diabetes treatment, offering smart solutions like smart insulin pens and Dose Check, an application for insulin dose guidance. Through a strategic collaboration with Aspen Pharmaceuticals, Novo Nordisk A/S produces insulin products. Established in 1923, the company is headquartered in Bagsværd, Denmark. To learn more about Novo Nordisk A/S, visit their website at

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novo Nordisk A/S (NVO) - Stock Price & Dividends

NVO Stock Overview

Market Cap in USD 535,549m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1982-01-04

NVO Stock Ratings

Fundamental 8.83
Dividend 7.03
Growth 5y 9.45
Rel. Performance vs Sector 4.02
Analysts 4.11
Fair Price Total Ret. 152.62
Fair Price DCF 429.94

NVO Dividends

Yield 12m 0.61%
Yield on Cost 5y 3.19%
Dividends CAGR 5y 10.95%
Payout Consistency 78.8%

NVO Growth Ratios

Growth 12m 71.70%
Growth Correlation 12m 74%
Growth Correlation 3m 79%
CAGR 5y 39.40%
CAGR / Mean Drawdown 8.10
Sharpe Ratio 12m 2.14
Alpha vs SP500 12m 48.80
Beta vs SP500 5y weekly 0.71
CAPM 7.18%
Average Daily Range 2m 1.65%
Regime Oscillator 58.90
Volatility GJR Garch 1y 26.35%
Price / SMA 50 9.44%
Price / SMA 200 27.64%
Current Volume 3073.3k
Average Volume 20d 5609.7k

External Links for NVO Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of NVO stocks?
As of February 29, 2024, the stock is trading at USD 121.54 with a total of 3,073,300 shares traded.
Over the past week, the price has changed by +0.50%, over one month by +11.48%, over three months by +19.83% and over the past year by +71.10%.
Why is NVO stock down?
Check with which Index or Commodity NVO has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return NVO Return S&P 500
1 Month 11.48% 3.05%
3 Months 19.83% 11.73%
12 Months 71.10% 29.22%
What is the forecast for NVO stock price target?
According to ValueRays Forecast Model, NVO Novo Nordisk A/S will be worth about 168.9 in February 2025. The stock is currently trading at 121.54. This means that the stock has a potential upside of +38.98%.
Issuer Forecast Upside
Wallstreet Target Price 125.7 3.4%
Analysts Target Price 80.4 -33.8%
ValueRay Target Price 168.9 39.0%

Understanding Novo Nordisk: From Origins to Modern Market

History of Novo Nordisk

Novo Nordisk has its origins in early 20th-century Denmark, with its foundation deeply rooted in the discovery and development of insulin. Established from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1989, it has a legacy of innovation and dedication towards diabetes care. This merger was not just a merging of names but of decades of research, commitment, and a shared mission to defeat diabetes and other serious chronic conditions.

Core Business

At the heart of Novo Nordisk's operations is the commitment to be a driving force in diabetes care. The company leads the market in diabetes treatments, providing a wide range of products including insulin, GLP-1 receptor agonists, and treatments for obesity. Diabetes care, however, is only part of the picture. The company is also invested in haemophilia treatments, growth hormone therapy, and hormone replacement therapy – addressing a wider spectrum of chronic diseases and conditions.

Side Business and Extensions

Beyond its primary focus, Novo Nordisk has ventured into areas such as obesity management, offering innovative solutions and treatments. This includes weight management products that complement its diabetes care portfolio, underscoring its holistic approach to tackling complex health problems. Moreover, the company has a growing presence in the biopharmaceutical sector, exploring treatments in new therapeutic areas, reflecting its ongoing commitment to push the boundaries of healthcare and improve patient outcomes.

Current Market Status

As of the current market landscape, Novo Nordisk A/S (NYSE:NVO) enjoys a robust position. Supported by a strong product pipeline and a steadfast focus on research and development, it continues to grow its global market share. The company's financial health remains solid, demonstrating resilience and adaptability even in the face of economic fluctuations and changing healthcare environments. With a clear strategic direction and dedication to innovation, Novo Nordisk is well-equipped to navigate future challenges and opportunities in the healthcare sector.